Dr Thickett’s research interests are predominantly in the areas of primary lung epithelial and macrophage biology, murine models of acute lung injury, epithelial mesenchymal transition and translational clinical trials to prevent and treat acute lung injury and idiopathic pulmonary fibrosis. He has been and continues to be a co-investigator or principal investigator on a number of clinical trials successfully obtaining an MRC DCS grant for 2 clinical trials of vitamin D therapy to prevent lung injury following oesophagectomy.
Dr Thickett is currently involved in the following studies:
Translational science lead, chairman of clinical endpoints committee and steering group member for BALTI- PREVENTION
PI of a phase II trial of simvastatin in healthy elderly patients
PI of a phase II study of the pharmcogenetics of vitamin D replacement in tuberculosis
PI of a phase II open label dosing study of vitamin D following oesophagectomy
the PI of a phase II study vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO)
PI of a phase II study of simvastatin to modify neutrophil function in older patients with septic pneumonia (SNOOPI)
TSC member of TIPAC-2 steering committee – a trial of septrin therapy in idiopathic pulmonary fibrosis
